Mounjaro

• Tirzepatide is a synthetic peptide of 39 amino acids.
• It acts as an agonist at two receptors at once: GIP and GLP-1.
• The molecule carries a fatty acid attached to the chain, which the literature links to an extended duration of action.
• Supplied as a lyophilised powder for reconstitution.

• Published work describes an additive effect of simultaneous GIP and GLP-1 receptor activation compared with GLP-1 agonism alone.
• GLP-1 agonism is associated with satiety signalling and with slowed gastric emptying.
• The role of the GIP pathway in lipid metabolism and in the insulin response is the subject of further investigation.

• Glycaemic control and insulin secretion.
• Energy balance and the regulation of food intake.
• Lipid metabolism and the distribution of fat mass.

Tirzepatide has an extensive clinical literature, including controlled trials.

That changes nothing about what this item is for: data from clinical trials

apply to an authorised medicine given under medical supervision, not to a

reference substance in a laboratory.

Tirzepatide is the active substance of an authorised medicine. This item is a

**reference standard intended strictly for laboratory and research use**.

It is not a medicine, it is not authorised for administration to humans, and it

must not be used for diagnosis, prevention or treatment. We provide no dosing,

protocols or health advice. The name is given to identify the active substance;

this is neither the originator medicine nor an equivalent of it. The purchaser

is responsible for complying with the law in force at the place of delivery.